SCHEMBL10126552

SCHEMBL10126552

CSc1nc(Cl)c(C(N)=O)c(Nc2ccc(F)c(C(=O)N3CCCCC3)c2)n1

nearest known ligand 0.42

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
IRAK4 Q9NWZ3 1/20 0.42
CNR2 P34972 4/20 0.42
CNR1 P21554 1/20 0.42
GRM5 P41594 2/20 0.38
TSHR P16473 1/20 0.38
HPGD P15428 4/20 0.38
ALDH1A1 P00352 3/20 0.37
NPSR1 Q6W5P4 3/20 0.37
KDM4E B2RXH2 2/20 0.37
HTT P42858 1/20 0.37
SMN1; SMN2 Q16637 2/20 0.36
LMNA P02545 1/20 0.36
PTK6 Q13882 1/20 0.36
EPHX2 P34913 1/20 0.36
MAPT P10636 2/20 0.35
CCNT1 O60563 1/20 0.35
CCNE1 P24864 1/20 0.35
CDK2 P24941 1/20 0.35
CDK9 P50750 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10126557 0.91 EPHX2 (0.44) CNR2CNR1TSHRSMN1; SMN2EPHX2
SCHEMBL10126599 0.91 CNR2 (0.43) CNR2CNR1GRM5HPGDALDH1A1
SCHEMBL328277 0.90 CNR2 (0.43) CNR2CNR1GRM5TSHRHPGD
SCHEMBL17340270 0.89 IRAK4 (0.40) IRAK4CNR2CNR1GRM5TSHR
SCHEMBL10126505 0.89 PTK6 (0.45) CNR2CNR1GRM5HPGDPTK6
SCHEMBL10156673 0.87 PTK6 (0.39) CNR2CNR1GRM5NPSR1SMN1; SMN2
SCHEMBL16305321 0.86 HPGD (0.50) CNR2CNR1GRM5TSHRHPGD
SCHEMBL10126559 0.85 CA1 (0.40) HPGDALDH1A1KDM4EHTTLMNA
SCHEMBL10157057 0.83 SCN9A (0.43)
SCHEMBL10127101 0.82 CAMK1D (0.47) IRAK4CNR2CNR1TSHRCCNT1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9487491-B2 Diamino heterocyclic carboxamide compound ASTELLAS PHARMA INC. (JP) 2016-11-08 US disclosed
US-9487491-B2 Diamino heterocyclic carboxamide compound ASTELLAS PHARMA INC. (JP) 2016-11-08 US disclosed
US-8969336-B2 Diamino heterocyclic carboxamide compound ASTELLAS PHARMA INC. (JP) 2015-03-03 US disclosed
US-8969336-B2 Diamino heterocyclic carboxamide compound ASTELLAS PHARMA INC. (JP) 2015-03-03 US disclosed
US-20140371196-A1 DIAMINO HETEROCYCLIC CARBOXAMIDE COMPOUND ASTELLAS PHARMA INC. (JP) 2014-12-18 US disclosed
US-20140371196-A1 DIAMINO HETEROCYCLIC CARBOXAMIDE COMPOUND ASTELLAS PHARMA INC. (JP) 2014-12-18 US disclosed
US-20120040968-A1 DIAMINO HETEROCYCLIC CARBOXAMIDE COMPOUND WATERS TECHNOLOGIES CORPORATION (US) 2012-02-16 US disclosed
US-20120040968-A1 DIAMINO HETEROCYCLIC CARBOXAMIDE COMPOUND WATERS TECHNOLOGIES CORPORATION (US) 2012-02-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140371196-A1 DIAMINO HETEROCYCLIC CARBOXAMIDE COMPOUND EML4, ALK, ERBB4 IRAK4 403/4885CNR2 1453/4885CNR1 1904/4885
US-20120040968-A1 DIAMINO HETEROCYCLIC CARBOXAMIDE COMPOUND EML4, ALK, ERBB4 IRAK4 403/4885CNR2 1453/4885CNR1 1904/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.